Valuation: Labcorp Holdings Inc.

Capitalization 20.53B 17.67B 16.14B 15.41B 28.23B 1,970B 28.73B 194B 74.9B 934B 77.05B 75.41B 3,259B P/E ratio 2026 *
18x
P/E ratio 2027 * 16.2x
Enterprise value 25.17B 21.65B 19.78B 18.89B 34.6B 2,415B 35.21B 237B 91.8B 1,145B 94.43B 92.43B 3,995B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.59x
Free-Float
99.64%
Yield 2026 *
1.16%
Yield 2027 * 1.17%
1 day-1.43%
1 week-1.46%
Current month-2.49%
1 month-6.12%
3 months-11.40%
6 months-6.18%
Current year-0.19%
1 week 250.13
Extreme 250.13
258.77
1 month 248.59
Extreme 248.5883
279.71
Current year 245
Extreme 245
292.02
1 year 239.75
Extreme 239.75
293.72
3 years 191.97
Extreme 191.97
293.72
5 years 191.97
Extreme 191.97
317.17
10 years 98.02
Extreme 98.02
317.17
Change 5d. change 1-year change 3-years change Capi.($)
-1.43%-1.46%+1.68%+12.34% 20.53B
-1.30%+5.90%+58.57%+39.27% 122B
-2.24%-2.80%+9.73%+52.42% 93.84B
-0.69%-5.27%-8.75%+39.67% 25.4B
-0.71%-0.42%+5.78%+40.94% 20.66B
0.00%-1.57%-17.91%-20.92% 20.52B
-0.95%+3.30%+19.89%+176.64% 16.94B
+0.26%-9.06%-1.11%+33.74% 15.1B
+3.72%+0.55%+39.09%+106.22% 12.82B
+0.62%-0.32%-26.79%-14.98% 11.62B
Average -0.27%-1.11%+8.02%+46.53% 35.98B
Weighted average by Cap. -1.08%+0.49%+22.66%+44.73%

Financials

2026 *2027 *
Net sales 14.71B 12.65B 11.56B 11.04B 20.22B 1,411B 20.58B 139B 53.65B 669B 55.19B 54.02B 2,335B 15.42B 13.27B 12.12B 11.57B 21.2B 1,479B 21.57B 145B 56.25B 701B 57.86B 56.63B 2,447B
Net income 1.13B 972M 888M 848M 1.55B 108B 1.58B 10.65B 4.12B 51.37B 4.24B 4.15B 179B 1.24B 1.06B 971M 928M 1.7B 119B 1.73B 11.66B 4.51B 56.22B 4.64B 4.54B 196B
Net Debt 4.63B 3.99B 3.64B 3.48B 6.37B 445B 6.48B 43.71B 16.9B 211B 17.39B 17.02B 735B 3.94B 3.39B 3.1B 2.96B 5.42B 378B 5.51B 37.18B 14.38B 179B 14.79B 14.47B 626B
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Employees
66,385
Date Price Change Volume
15/05/26 250.40 $ -1.43% 568,669
14/05/26 254.02 $ -0.16% 540,476
13/05/26 254.42 $ -1.14% 475,785
12/05/26 257.35 $ +0.89% 732,390
11/05/26 255.08 $ +0.38% 677,620
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
250.40USD
Average target price
310.06USD
Spread / Average Target
+23.83%

Quarterly revenue - Rate of surprise